The initial immune response to HIV and immune system activation determine the outcome of HIV disease - PubMed (original) (raw)

Affiliations

PMID: 1675678

The initial immune response to HIV and immune system activation determine the outcome of HIV disease

H W Sheppard et al. J Acquir Immune Defic Syndr (1988). 1991.

Abstract

A study was conducted to assess the relative contribution of the HIV-1-specific immune response and -nonspecific immune activation to HIV disease progression. The titer of antibody to the p24 core protein and the concentration of serum neopterin were measured in 238 HIV-1-seropositive subjects in a prospective cohort study of homosexual men. Antibody titers were extremely variable among cohort participants but relatively stable over time, suggesting inherent differences in the initial immune response capacity. Neopterin concentrations were also variable at cohort entry but generally increased over time. These two markers, measured at cohort entry, had powerful and independent predictive value for the development of AIDS up to 54 months before diagnosis. Subjects with low antibody titers and high levels of neopterin, had the highest incidence of AIDS (60% over 54 months). Patients with low antibody or high neopterin alone had an intermediate risk (34% incidence) and less than 10% of those with high antibody and low neopterin developed AIDS. We propose that the initial immune response to HIV and virus-mediated immune system activation are independent and innately variable components of an individual's response to HIV infection that interact to determine the clinical outcome.

PubMed Disclaimer

Cited by

Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.
French MA, Abudulai LN, Fernandez S. French MA, et al. Vaccines (Basel). 2013 Aug 9;1(3):328-42. doi: 10.3390/vaccines1030328. Vaccines (Basel). 2013. PMID: 26344116 Free PMC article. Review.
Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells.
Chakrabarti L, Isola P, Cumont MC, Claessens-Maire MA, Hurtrel M, Montagnier L, Hurtrel B. Chakrabarti L, et al. Am J Pathol. 1994 Jun;144(6):1226-37. Am J Pathol. 1994. PMID: 8203463 Free PMC article.
Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus.
Lackner AA, Vogel P, Ramos RA, Kluge JD, Marthas M. Lackner AA, et al. Am J Pathol. 1994 Aug;145(2):428-39. Am J Pathol. 1994. PMID: 8053500 Free PMC article.
Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.
Fahey JL. Fahey JL. Clin Diagn Lab Immunol. 1998 Sep;5(5):597-603. doi: 10.1128/CDLI.5.5.597-603.1998. Clin Diagn Lab Immunol. 1998. PMID: 9729522 Free PMC article. Review. No abstract available.
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.
Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y, Markowitz M, Ho DD, Moore JP. Morris L, et al. J Exp Med. 1998 Jul 20;188(2):233-45. doi: 10.1084/jem.188.2.233. J Exp Med. 1998. PMID: 9670036 Free PMC article. Clinical Trial.

The initial immune response to HIV and immune system activation determine the outcome of HIV disease - PubMed (original) (raw)